Camlin Fine Sciences Ltd (CAMLINFINE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Camlin Fine Sciences Ltd on NSE and BSE, with an AI summary of each filing.
Audio Recording of the Investor Call - Q2 & H1FY27
Audio / Video · 04 Nov 2026, 1:21 am
Camlin Fine Sciences Releases Audio Recording for Q2 & H1 FY27 Earnings Call Camlin Fine Sciences has made available the audio recording of its earnings conference call held on 3rd Nov'26 discussing the un-audited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. The meeting was attended by key management executives, including Managing Director Nirmal Momaya, President - Strategy & Global CFO Santosh Parab, and CFO Pankaj Pandey. The company confirmed that discussions were based strictly on publicly available information with no unpublished price-sensitive information shared, ensuring regulatory compliance.
Investor Presentation - Q2 & H1FY27
Investor Presentation · 03 Nov 2026, 9:35 pm
Camlin Fine Sciences Reports Q2 FY27 Results; Plans Rights Issue Camlin Fine Sciences reported Q2 FY27 continuing operations revenue of Rs 4,914.7 mn, up 9.15% YoY, driven by 26% growth in Straights and 25% in Blends, offset by a 41% drop in Aroma. Adjusted EBITDA fell to Rs 22.3 mn (0.45% margin) due to elevated raw material costs, freight expenses, and Rs 51 mn idle maintenance at Dahej. Net loss stood at Rs 280.8 mn. The board approved raising up to Rs 2,500 mn via a rights issue, and acquired an additional 11% stake in Vinpai for Rs 201 mn.
Camlin Fine Sciences Limited has informed the Exchange regarding Outcome of Board Meeting for raising of fund by way of issue of equity shares held on November 03, 2026.
Outcome · 03 Nov 2026, 9:19 pm
Camlin Fine Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 03 Nov 2026, 9:17 pm
Outcome of Board Meeting dated November 3, 2026
Outcome · 03 Nov 2026, 9:14 pm
Un-audited Financial Results for the quarter and half year ended September 30, 2026
Financial Result · 03 Nov 2026, 9:11 pm
Camlin Fine Sciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 4,915 (+9.2% YoY | -5.5% QoQ) ■ EBITDA: 22.3 (-93.7% YoY | -75.9% QoQ) ■ EBITDA Margin (%): 0.5 (-746 bps YoY | -133 bps QoQ) ■ PAT: -279 (-93.6% YoY | +12.1% QoQ) ■ EPS (INR): -1.45 (-88.3% YoY | +12.1% QoQ) Camlin Fine Sciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance Specialty Ingredients ■ Revenue: 4,079 (+26.2% YoY | +1.6% QoQ) ■ EBIT: 328 (-8.6% YoY | +28.8% QoQ) ■ EBIT Margin (%): 8.0 (-307 bps YoY | +169 bps QoQ) Aroma ■ Revenue: 472 (-40.9% YoY | -39.1% QoQ) ■ EBIT: -109 (Profit to Loss YoY | -222.1% QoQ) ■ EBIT Margin (%): -23.1 (Profit to Loss YoY | -1873 bps QoQ) Performance Chemicals & Others ■ Revenue: 1,857 (+18.1% YoY | +6.2% QoQ) ■ EBIT: -197 (-119.5% YoY | -342.9% QoQ) ■ EBIT Margin (%): -10.6 (-490 bps YoY | -805 bps QoQ)
Enclosed
Others (Uncategorized) · 30 Oct 2026, 10:37 pm
Camlin Fine Sciences Receives SEBI Administrative Warning Over Shareholding Disclosures Camlin Fine Sciences received an administrative warning from SEBI on 30th Oct'26 regarding historical shareholding filings from quarters ended 30th Jun'16 to 31st Mar'23. The regulator cited violations of LODR Regulations 31 and 4 due to the incorrect classification of promoter-related individuals as public shareholders. The company has retrospectively rectified these filings. SEBI advised the company and its board to enhance compliance standards to prevent future lapses, warning of potential enforcement action upon recurrence. The company confirmed zero financial or operational impact from the warning.
Schedule of Investor Meet
Intimation · 03 Nov 2026, 5:30 pm
Camlin Fine Sciences Schedules Q2 & H1 FY27 Earnings Call Camlin Fine Sciences Limited will host an earnings conference call on 3rd Nov'26 at 05:30 PM IST to discuss its unaudited operational and financial performance for Q2 and H1 ended 30th Sep'26 (Q2 & H1 FY27). Senior management participants include Chairman & Managing Director Ashish Dandekar, Managing Director Nirmal Momaya, and CFO Santosh Parab. Discussions will be limited to publicly available information with no unpublished price-sensitive information shared.
To consider Fund Raising
Intimation · 03 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 03 Nov 2026, 5:30 am
Camlin Fine Sciences Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Fund raising.
Intimation · 03 Nov 2026, 5:30 am
Camlin Fine Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the un-audited Standalone ....
Intimation · 03 Nov 2026, 5:30 am
Camlin Fine Sciences Board to Consider Q2 Results and Rights Issue Camlin Fine Sciences has scheduled its Board of Directors meeting for 3rd Nov'26 to evaluate and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Additionally, the board will consider a fundraising proposal via a rights issue of equity shares or other securities, subject to regulatory approvals. The company's trading window remains closed for designated persons from 1st Oct'26 through 5th Nov'26.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 29, 2026 for Ashish Subhash Dandekar
Encumbered Shares - Invocation / Release · 29 Oct 2026, 9:20 pm
Camlin Fine Sciences Promoter Ashish Dandekar Pledges Additional Shares Promoter Ashish Subhash Dandekar, holding a 10.30% stake (1,97,78,510 shares) in Camlin Fine Sciences Ltd., created fresh pledges on 27th Oct'26 totaling 13,60,000 shares (0.71% of total share capital). The pledge includes 8,10,000 shares (0.42%, valued at Rs 6.78 cr) in favor of Aditya Birla Capital Limited and 5,50,000 shares (0.29%, valued at Rs 4.61 cr) in favor of SKS Fincap Private Limited to cover security shortfalls for financial assistance. Total encumbered promoter shares increased to 1,63,10,000 shares (8.49% of total share capital, representing 82.46% of his holding).
Intimation of completion of tenure of Independent Director of the Company.
Change in Management · 18 Oct 2026, 4:28 pm
Camlin Fine Sciences: Independent Director Pradip Kanakia Completes Five-Year Board Tenure Camlin Fine Sciences Limited announced that Pradip Kanakia (DIN: 00770347) ceased to serve as an Independent Director of the company effective 18th Oct'26. The cessation follows the routine completion of his five-year consecutive term on the board, pursuant to regulatory disclosures under Regulation 30 of the SEBI Listing Regulations.
Allotment of ESOP
Others (Uncategorized) · 17 Oct 2026, 12:20 am
Camlin Fine Sciences Allots 1,200 Equity Shares Under ESOP Scheme Camlin Fine Sciences Limited has allotted 1,200 equity shares of face value Re. 1 each on 16th Oct'26, pursuant to the exercise of vested options under its CFSL Employees Stock Option Scheme, 2018 (ESOP - 2018). The options were exercised at a price of Rs. 85.00 per share (including a premium of Rs. 84.00 per share). Following this allotment, the company's paid-up equity share capital increased to Rs. 19,20,97,813, comprising 19,20,97,813 equity shares. The newly allotted shares carry no lock-in restrictions and rank pari-passu with existing equity.
Appointment of Additional Non-executive Independent Director of the Company.
Change in Management · 09 Sept 2026, 9:09 pm
Camlin Fine Sciences Appoints Atul Pradhan as Independent Director Camlin Fine Sciences Limited approved the appointment of Mr. Atul Pradhan as an Additional Non-Executive Independent Director for a five-year term effective 11th Sep'26, subject to shareholder approval via postal ballot. Mr. Pradhan, former Head of Management Consulting at KPMG India and co-founder of Transfolign Consulting, brings extensive global governance, M&A, and business transformation expertise across diverse sectors. He has no familial relationships with existing board members and is not debarred from holding directorial office by SEBI or any regulatory authority.
Transcript of the Earnings Call Q1FY27
Transcript · 18 Aug 2026, 12:10 am
Investor Call Recording Q1 FY27
Audio / Video · 12 Aug 2026, 12:23 am
Camlin Fine Sciences Publishes Q1 FY27 Earnings Call Recording Camlin Fine Sciences has made the audio recording of its Aug 11, '26 conference call available on its website. The call discussed the un-audited consolidated and standalone financial results for the quarter ended Jun 30, '26. Management representation included the Chairman & MD, MD, and CFO. The company confirmed that discussions were based on publicly available information and no unpublished price sensitive information (UPSI) was shared during the event. This disclosure complies with SEBI Listing Regulations.
Investor Presentation Q1 FY27
Investor Presentation · 11 Aug 2026, 10:10 pm
Camlin Fine Sciences Q1FY27: Record Revenue Overshadowed by Margin Pressure Camlin Fine Sciences reported its highest-ever quarterly revenue of Rs 5,199 mn for Q1FY27, up 27.5% YoY, driven by strong growth across all segments. However, profitability was severely impacted, with the adjusted EBITDA margin contracting to 3.4% from 5.0% YoY due to higher raw material costs, limited pass-through, and increased logistics expenses. Consequently, the company posted a net loss of Rs 318 mn from continuing operations, compared to a Rs 31.5 mn loss YoY, further impacted by a Rs 111 mn exceptional item.
Outcome of Board Meeting dated August 11, 2026
Outcome · 11 Aug 2026, 9:45 pm
Camlin Fine Sciences Posts Q1FY27 Net Loss Amid Higher Revenue Camlin Fine Sciences reported a consolidated net loss of Rs. 336.22 million for Q1FY27, a significant decline from a profit of Rs. 862.77 million in Q4FY26 and a loss of Rs. 106.81 million in Q1FY26. Revenue from operations grew 27.8% YoY to Rs. 5,198.79 million. The loss was impacted by a Rs. 111.10 million exceptional item and higher expenses, which rose 29.9% YoY. The Specialty Ingredients segment was the primary revenue driver, contributing Rs. 4,013.17 million. Basic EPS stood at Rs. (1.65).
Un-audited Financial Results for the quarter ended June 30, 2026
Financial Result · 11 Aug 2026, 9:43 pm
Camlin Fine Sciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 5,199 (+27.5% YoY | +22.4% QoQ) ■ EBITDA: 92.8 (-54.3% YoY | -56.2% QoQ) ■ EBITDA Margin (%): 1.8 (-319 bps YoY | -320 bps QoQ) ■ PAT: -317 (-218.3% YoY | Profit to Loss QoQ) ■ EPS (INR): -1.65 (-211.3% YoY | Profit to Loss QoQ) Camlin Fine Sciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) Segmental Performance Specialty Ingredients ■ Revenue: 4,013 (+36.7% YoY | +18.4% QoQ) ■ EBITDA: 255 (-15.1% YoY | -3.3% QoQ) ■ EBITDA Margin (%): 6.3 (-387 bps YoY | -142 bps QoQ) Aroma ■ Revenue: 774 (+36.5% YoY | +66.9% QoQ) ■ EBITDA: -33.8 (-65.6% YoY | +61.6% QoQ) ■ EBITDA Margin (%): -4.4 (-77 bps YoY | +1460 bps QoQ) Performance Chemicals & Others ■ Revenue: 1,749 (+15.7% YoY | +26.9% QoQ) ■ EBITDA: -44.4 (+42.0% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -2.5 (+252 bps YoY | Profit to Loss QoQ)
Scrutinizers Report with Voting Results of 33rd AGM
Annual General Meeting · 11 Aug 2026, 9:06 pm
Proceedings of the 33rd AGM
Annual General Meeting · 11 Aug 2026, 9:02 pm
Schedule of Investor Meet - Q1FY27 Earnings Call
Intimation · 11 Aug 2026, 5:00 pm
Camlin Fine Sciences Schedules Q1 FY27 Earnings Call for Aug 11, 2026 Camlin Fine Sciences (CAMLINFINE) will host an earnings call on 11th Aug'26 at 5:00 PM IST to discuss its unaudited financial results for Q1 FY27, the quarter ending 30th Jun'26. Senior management, including the Chairman & MD Ashish Dandekar, MD Nirmal Momaya, and CFO Santosh Parab, will lead the discussion with investors and analysts. The call will focus on the company's operational and financial performance, based on publicly available information. The scheduled date is subject to potential changes.
Camlin Fine Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the Un-audited Standalone ....
Intimation · 11 Aug 2026, 5:30 am
Camlin Fine Sciences Board Meeting Set for Aug 11 to Approve Q1FY27 Results Camlin Fine Sciences has scheduled a Board of Directors meeting for 11th Aug'26 to consider and approve its un-audited standalone and consolidated financial results for the quarter ended 30th Jun'26. The company also confirmed the trading window for its equity shares has been closed from 1st Jul'26 and will remain closed until 48 hours after the financial results are made public. This meeting is a key event for investors tracking the company's Q1FY27 performance.